HENSOLDT AG held its 2025 Annual General Meeting in Taufkirchen, Munich, with significant shareholder attendance. The meeting saw 67.98% of the share capital represented, and all agenda items received ...

Formycon AG and Fresenius Kabi have announced the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar, in Canada. This product is available in both subcutaneous and intravenous ...